Policosanol

Alternative Medicine Review

Volumn 9, Issue 3, 2004, Pages 312-317

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACIPIMOX; ATORVASTATIN; MEVINOLIN; PLANT EXTRACT; POLICOSANOL; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TICLOPIDINE;

BIOCHEMISTRY; BODY WEIGHT DISORDER; BULIMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG INTERACTION; DRUG MECHANISM; DRUG NUTRIENT INTERACTION; DRUG STRUCTURE; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NONHUMAN; NUTRIENT; PHYTOTHERAPY; PLANT PRODUCT; POLYURIA; REVIEW; SUGARCANE; WEIGHT REDUCTION;

EID: 4644227274     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Arruzazabala ML, Noa M, Menendez R, et al. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. Braz J Med Biol Res 2000;33:835-840.
2. Menendez R, Amor AM, Gonzalez R, et al. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 1996;29:253-257.
3. Menendez R, Amor AM, Rodeiro I, et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 2001;32:8-12.
4. Menendez R, Fernandez SI, Del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 1994;27:199-203.
5. Menendez R, Fraga V, Amor MA, et al. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation. Physiol Behav 1999;67:1-7.
6. Menendez R, Mas R, Amor MA, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000;50:255-262.
7. Noa M, Mas R, Mesa R. Effect of policosanol on intimal thickening in rabbit cuffed carotid artery. Int J Cardiol 1998;67:125-132.
8. Noa M, Mas R, Mesa R. A comparative study of policosanol vs. lovastatin on intimal thickening in rabbit cuffed carotid artery. Pharmacol Res 2001;43:31-37.
9. Carbajal D, Arruzazabala ML, Valdes S, Mas R. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 1998;58:61-64.
10. Castano G, Mas R, Arruzazabala M, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999;29:105-116.
11. Valdes S, Arruzazabala MI, Fernandez L, et al. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res 1996;16:67-72.
12. Arruzazabala ML, Valdes S, Mas L, et al. Effect of policosanol successive dose increase on platelet aggregation in healthy volunteers. Pharmacol Res 1996;34:181-185.
13. Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 1997;36:293-297.
14. Arruzazabala ML, Mas R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React 1998;20:119-124.
15. Pons P, Mas R, Illnait J, et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia. Curr Ther Res Clin Exp 1992;52:507-513.
16. Aneiros E, Calderon B, Mas R, et al. Effect of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res Clin Exp 1993;54:304-312.
17. Pons P, Rodriguez M, Mas R, et al. One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 1994;55:1084-1092.
18. Pons P, Rodriquez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14:27-33.
19. Canetti M, Moreira M, Illnait J, et al. One-year study of the effect of policosanol on lipid profile in patients with type II hypercholesterolemia. Adv Ther 1995;12:245-254.
20. Aneiros E, Mas R, Calderon B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 1995;56:176-182.
21. Castano G, Mas R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res Clin Exp 1995;56:296-304.
22. Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia. Int J Clin Pharmacol Res 1995;15:159-165.
23. Castano G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study. Curr Ther Res Clin Exp 1995;56:819-827.
24. Castano G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 1996;57:691-699.
25. Batista J, Stusser R, Saez F, Perez B. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Int J Clin Pharmacol Ther 1996;34:134-137.
26. Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999;65:439-447.
27. Castano G, Mas R, Fernandez JC, et al. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol 2001;56A:M186-M192.
28. Castano G, Mas R, Fernandez L, et al. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 2001;21:43-57.
29. Castano G, Mas R, Fernandez JC, et al. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R D 2002;3:159-172.
30. Crespo N, Alvarez R, Mas R, et al. Effects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study. Curr Ther Res Clin Exp 1997;58:44-51.
31. Torres O, Agramonte A, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995;18:393-397.
32. Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999;29:117-127.
33. Castano G, Mas R, Fernandez L, et al. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology 2003;54:25-38.
34. Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000;14:187-195.
35. Mirkin A, Mas R, Martinto M, et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res 2001;21:31-41.
36. Ortensi G, Gladstein J, Valli H, Tesone PA. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res Clin Exp 1997;58:390-401.
37. Illnait J, Castano G, Mas R, Fernandez JC. A comparative study on the efficacy and tolerability of policosanol and simvastatin for treating type II hypercholesterolemia. Can J Cardiol 1997;13:342B.
38. Benitez M, Romero C, Mas R, et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 1997;58:859-867.
39. Castano G, Mas R, Fernandez JC, et al. Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors. Curr Ther Res Clin Exp 2000;61:137-146.
40. Pons P, Illnait J, Mas R, et al. A comparative study of policosanol versus probucol in patients with hypercholesterolemia. Curr Ther Res Clin Exp 1997;58:26-35.
41. Alcocer L, Fernandez L, Compos E, Mas R. A comparative study of policosanol versus acipimox in patients with type II hypercholesterolemia. Int J Tissue React 1999;21:85-92.
42. Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 2003;20:153-163.
43. Zardoya R, Tula L, Castano G, et al. Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function. Curr Ther Res Clin Exp 1996;57:568-577.
44. Castano G, Mas R, Roca J, et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 1999;50:123-130.
45. Castano G, Mas R, Fernandez L, et al. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001;52:115-125.
46. Castano G, Mas R, Gamez R, et al. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology 2004;55:361-371.
47. Batista J, Strusser R, Padron R, et al. Functional improvement in coronary artery disease after 20 months of lipid-lowering therapy with policosanol. Adv Ther 1996;13:137-148.
48. Stusser R, Batista J, Padron R, et al. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients. Int J Clin Pharmacol Ther 1998;36:469-473.
49. Batista J, Stusser R, Penichet M, Uguet E. Doppler-ultrasound pilot study of the effects of long-term policosanol therapy on carotid-vertebral atherosclerosis. Curr Ther Res Clin Exp 1995;56:906-914.
50. Fernandez L, Mas R, Illnait J, Fernandez JC. Policosanol: results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res Clin Exp 1998;59:717-722.
51. Celia AL, Mas R, Hernandez C, et al. A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol Lett 1994;70:77-87.
52. Aleman CL, Mas R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: a 24 month study. Teratog Carcinog Mutagen 1994;14:239-249.
53. Mesa AR, Mas R, Noa M, et al. Toxicity of policosanol in beagle dogs: one-year study. Toxicol Lett 1994;73:81-90.
54. Rodreguez-Echenigue C, Mesa R, Mas R, et al. Effects of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol 1994;32:565-575.
55. Aleman CL, Noa M, Elias EC, et al. Carcinogenicity of policosanol in mice: an 18-month study. Food Chem Toxicol 1995;33:573-578.
56. Rodriguez MD, Garcia H. Evaluation of peri-and post-natal toxicity of policosanol in rats. Teratog Carcinog Mutagen 1998;18:1-7.
57. Rodriguez MD, Garcia H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen 1994;14:107-113.
58. Rodriguez MD, Sanchez M, Garcia H. Multigeneration reproduction study of policosanol in rats. Toxicol Lett 1997;90:97-106.